Zoetis

ZTS

Market cap $50.9B

The mean of analysts' price targets for Zoetis (ZTS) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

The latest trading day saw Zoetis (ZTS) settling at $117.86, representing a -1.78% change from its previous close.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The April 2026 Top 25 High Growth Dividend Stocks list targets quality companies trading below intrinsic value, averaging a 1.52% yield and 17.7% five-year dividend growth. Screened stocks appear ~34% undervalued by dividend yield theory, with an estimated +21% annualized long-term return potential. MSCI, WING, ZTS, INTU, and MSFT stand out for attractive valuations, robust dividend growth, and strong projected EPS growth.

Zoetis offers broad diversification across hundreds of animal health products, with nearly equal U.S. and international revenue exposure. ZTS posted resilient Q4 2025 results, with 3% revenue growth, 5.7% EPS growth, and a robust 27%+ non-GAAP net margin, outperforming consensus. Key 2026 catalysts include launches of next-generation osteoarthritis drugs Portela and Lenivia, targeting improved compliance and expanded market reach.

Zoetis Inc. (ZTS) is rated a hold, as shares trade near fair value with limited upside despite sector leadership and defensive qualities. The company guides for 3-5% organic operational growth in 2026 and remains very shareholder-friendly, reflected in a 20% 5-year DPS growth and 6.6% buyback yield. Zoetis faces risks from pipeline concentration, potential margin pressure due to increasing competition and product setbacks, notably Librela's 32% sales decline due to safety concerns.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-pr.